Form 4: BioAtla Chief Medical Officer's Stock Holdings Adjusted for Routine Tax Withholding

BioAtla's Chief Medical Officer, Eric Sievers, had 2,729 shares of common stock withheld by the company to cover tax obligations related to the vesting of previously reported restricted stock units.

Summary

• Eric Sievers, Chief Medical Officer of BioAtla, Inc. (BCAB), reported a transaction on May 31, 2025, involving the company's common stock.
• The transaction, coded 'F', indicates shares withheld by the issuer to satisfy income tax and withholding obligations.
• A total of 2,729 shares were disposed of at a price of $0.409 per share for tax purposes.
• Following this transaction, Mr. Sievers beneficially owns 367,303 shares of BioAtla common stock directly.

Sentiment

Score: 5

Explanation: The document reports a routine administrative transaction (tax withholding for RSU vesting) which is neutral in sentiment. It is neither a positive nor a negative indicator for the company's operational or financial performance.

Positives

• The transaction is a result of the vesting and net settlement of previously reported restricted stock units (RSUs), indicating that compensation for the Chief Medical Officer has been realized.
• The withholding of shares for tax purposes is a standard and routine administrative process for RSU vesting, reflecting a normal course of business for employee compensation.

Negatives

• No direct negative implications are indicated by this routine tax withholding transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding BioAtla's future outlook.

Management Comments

• "This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units."

Industry Context

This filing is a routine insider transaction report (Form 4) detailing a compensation-related event for a senior executive. It does not provide information directly related to broader industry trends or competitive dynamics, but rather reflects standard practices for executive equity compensation in the biotechnology sector.

Related Party Transactions

• The transaction involves the withholding of shares by BioAtla from its Chief Medical Officer, Eric Sievers, to cover tax obligations related to his equity compensation (restricted stock units). This is a standard compensation-related transaction between the company and an executive.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine administrative transaction related to executive compensation and not a market sale or purchase.
• Employees: Reflects standard equity compensation practices for executives.
• Customers, Suppliers, Creditors: No direct impact.

Key Dates

Keywords

BioAtla, BCAB, Form 4, Eric Sievers, Chief Medical Officer, Insider Transaction, Stock Withholding, Restricted Stock Units, RSU Vesting, Beneficial Ownership